ANIX VS LIFW Stock Comparison
Performance
ANIX10/100
10/100
ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
LIFW10/100
10/100
LIFW returned -84.30% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
ANIX75/100
75/100
1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.
LIFW
"Analyst Price Targets" not found for LIFW
Sentiment
ANIX67/100
67/100
ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.
LIFW
"Sentiment" not found for LIFW
Technicals
ANIX11/100
11/100
ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
LIFW79/100
79/100
LIFW receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.
Earnings
ANIX61/100
61/100
ANIX has missed earnings 3 times in the last 20 quarters.
LIFW100/100
100/100
LIFW has missed earnings 1 times in the last 20 quarters.
Profit
ANIX10/100
10/100
Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
LIFW10/100
10/100
Out of the last 7 quarters, LIFW has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
ANIX34/100
34/100
ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.
LIFW100/100
100/100
LIFW has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Anixa Biosciences, Inc. Summary
Nasdaq / ANIX
Healthcare
Biotechnology
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
MSP Recovery, Inc. Class A Common Stock Summary
Nasdaq / LIFW
Healthcare
Medical - Healthcare Information Services
MSP Recovery, Inc. operates as a healthcare recoveries and data analytics company in the United States and Puerto Rico. The company offers claims recovery services, including services to related parties or third parties to assist entities with pursuit of claims recovery rights. It also provides Chase to pay service to assist its healthcare provider clients to identify in the first instance the proper primary insurer at the point of care and thereby avoid making a wrongful payment; and LifeWallet, a platform designed to locate and organize users' medical records. MSP Recovery, Inc. was founded in 2014 and is headquartered in Coral Gables, Florida.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ANIX to other companies in the same or a similar industry.